Company Performance Metrics
NeoGenesis Pharmaceuticals, Inc. is a drug discovery company which uses it
proprietary affinity-based screening technologies and integrated chemical
library and chemistry approaches to discover and develop a portfolio of small
molecule drugs, both for itself and for its collaboration partners. The
company's widely applicable and
unbiased affinity-based technologies, coupled
with its proprietary library of diverse drug-like compounds, provide
efficiency in lead discovery and optimization, NeoGenesis' core technology,
the Automated Ligand Identification System (ALIS), is a rapid, affinity-based
system for identifying and optimizing novel drug leads that in many cases may
not have been identified with traditional screening approaches. Coupled with
the company's NeoMorph compound library, ALIS enables the identification and
optimization of novel and selective drug leads against validated and emerging
new targets. The company was founded in 1997 and is headquartered in
Cambridge, Massachusetts.
